α-Glucosidase-IN-23 is an orally active inhibitor of α-glucosidase that can decrease blood glucose levels by inhibiting α-glucosidase (IC50 = 4.48 μM).

In cells D-glucose 6-phosphate (G6P) is generated when glucose is phosphorylated by hexokinase or glucokinase or by the conversion of glucose-1-phosphate by phosphoglucomutase during glycogenolysis. G6P lies at the beginning of both glycolysis and the pentose phosphate pathways. It also can be stored as glycogen when blood glucose levels are high.

YMU1 is a human thymidylate kinase (hTMPK) inhibitor. YMU1 stabilizes the conformation of ligand-induced degradation (LID) region of hTMPK and blocks the catalytic site or ATP-binding site.